v3.25.4
Shareholders' Equity - Sale of shares (Details)
$ / shares in Units, € in Thousands
1 Months Ended 12 Months Ended 16 Months Ended
Oct. 31, 2024
shares
Oct. 25, 2024
EUR (€)
shares
Oct. 25, 2024
USD ($)
shares
Oct. 31, 2024
EUR (€)
shares
Oct. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2024
EUR (€)
Dec. 31, 2025
shares
Sep. 30, 2024
USD ($)
Disclosure of classes of share capital [line items]                
Proceeds from issuing shares | €           € 71,635    
2024 shelf registration statement                
Disclosure of classes of share capital [line items]                
Maximum offering price in shelf registration statement | $               $ 300,000,000
At the market offerings with Cantor Fitzgerald and Co under shelf registration statement                
Disclosure of classes of share capital [line items]                
Maximum offering price in shelf registration statement | $               $ 75,000,000
Percentage of commission payable for gross proceeds from sales agreement               3.00%
Issue of ordinary shares (in shares)             0  
October 2024 underwritten public offering                
Disclosure of classes of share capital [line items]                
Issue of ordinary shares (in shares)       18,000,000 18,000,000      
Price per share | $ / shares         $ 3.5      
Proceeds from issuing shares       € 64,600 $ 69,790,000      
Payments for share issue costs | €       4,365        
Net proceeds from issuing shares | €       € 60,235        
Underwriters' option in connection to October 2024 underwritten public offering                
Disclosure of classes of share capital [line items]                
Issue of ordinary shares (in shares) 1,940,072              
Duration of underwriters' option       30 days 30 days      
Number of shares callable for options issued 2,700,000     2,700,000 2,700,000      
Share purchase agreement with Eli Lilly and Company                
Disclosure of classes of share capital [line items]                
Issue of ordinary shares (in shares)   3,523,538 3,523,538          
Proceeds from issuing shares   € 11,400 $ 12,300,000          
Purchase price cap, share purchase agreement | $     $ 15,000,000